HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.

Published in: American journal of clinical pathology (2022)

HHLA2 is frequently expressed in HCC. Positive HHLA2 correlates with higher CD8+ cell density and favorable prognosis. HHLA2 may be considered a potential therapeutic immune target in HCC.

Keyphrases

single cell
cell therapy
mesenchymal stem cells